Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $30.00

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) have received a consensus recommendation of "Buy" from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $30.00.

A number of equities analysts have issued reports on the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $47.00 price target on shares of Astria Therapeutics in a research note on Wednesday, May 14th. Wedbush reaffirmed an "outperform" rating and set a $28.00 target price (up previously from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday, March 11th. JMP Securities assumed coverage on shares of Astria Therapeutics in a report on Friday, January 31st. They issued an "outperform" rating and a $26.00 target price for the company. Finally, Citizens Jmp raised shares of Astria Therapeutics to a "strong-buy" rating in a research report on Friday, January 31st.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. KLP Kapitalforvaltning AS purchased a new position in Astria Therapeutics in the fourth quarter valued at about $41,000. Tower Research Capital LLC TRC raised its holdings in shares of Astria Therapeutics by 109.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock worth $47,000 after purchasing an additional 2,766 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of Astria Therapeutics in the 4th quarter worth approximately $50,000. Virtus ETF Advisers LLC purchased a new position in Astria Therapeutics in the fourth quarter valued at approximately $65,000. Finally, GAMMA Investing LLC grew its holdings in Astria Therapeutics by 1,127.4% during the first quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company's stock valued at $46,000 after purchasing an additional 7,971 shares during the period. Hedge funds and other institutional investors own 98.98% of the company's stock.

Astria Therapeutics Trading Down 3.9%

NASDAQ ATXS traded down $0.16 during mid-day trading on Friday, hitting $3.92. The company's stock had a trading volume of 245,437 shares, compared to its average volume of 371,487. The firm has a market capitalization of $221.22 million, a price-to-earnings ratio of -1.88 and a beta of 0.45. The company's 50 day simple moving average is $4.75 and its 200 day simple moving average is $7.14. Astria Therapeutics has a twelve month low of $3.56 and a twelve month high of $12.92.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.10). As a group, research analysts forecast that Astria Therapeutics will post -1.65 EPS for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.